生物医药ETF（512290）盘中涨超2.3%，生物医药行业格局变化或催化

Core Insights - The biopharmaceutical industry is characterized by a coexistence of competition and cooperation between China and the United States [1] - China's research and development capabilities in biotechnology are continuously improving, with the National Medical Products Administration approving 87 drugs in 2023, including 5 domestic innovative drugs [1] - The number of licensing transactions has increased from 15 in 2019 to 33 in 2023, and the share of clinical trials has risen from 3% in 2013 to 28% in 2023 [1] - The U.S. maintains an advantage in genetic engineering and vaccine development, but there is a dependency on Chinese raw materials for the supply chain, making it difficult to eliminate reliance on Chinese supplies in the short term [1] - Long-term technological breakthroughs are expected to reshape the global pharmaceutical industry chain [1] Industry Overview - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets [1] - The CS Biomedicine Index focuses on high-growth and innovative biopharmaceutical companies, aiming to reflect the overall development trend of China's biopharmaceutical industry [1]